

## Data Sharing Statement

Madhi SA, Baillie V, Cutland CL, et al. Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant. N Engl J Med. DOI: 10.1056/NEJMoa2102214.

Question	Authors' Response
Will the data collected for your study be made available to others?	Yes
Would you like to offer context for your decision?	—
Which data?	Complete de-identified patient data set
Additional information about data	—
How or where can the data be obtained?	Data will be made available upon request from the study statistician Dr Alane Izu (alane.izu@wits-vida.
When will data availability begin?	One year after trial completion
When will data availability end?	indefinite
Will any supporting documents be available?	—
Which supporting documents?	Analytic/Statistical code. Informed Consent Form
Additional information about supporting documents	—
How or where can supporting documents be obtained?	Documents will be posted on the wits-vida website (enabled by month and as being re-engineered) or will be made available upon request from the Principal Investigator Shabir Madhi - shabir.madhi@wits.ac.za
When will supporting documents availability begin?	With publication
When will supporting documents availability end?	indefinite
To whom will data be available?	Researchers whose proposed use if approved, including by the University of Witwatersrand Ethics committee as is the local requirement
For what type of analysis or purpose?	Any purpose to promote good science
By what mechanism?	With investigator support, after approval of a proposal, and with a signed data access agreement).
Any other restrictions?	Not to be used for commercial purposes unless agreement with institution
Additional information	No

This statement was posted on March 16, 2021, at NEJM.org.